Wholomics, a startup originating from Dana Farber and University College London, has introduced a metabolomics-based platform utilizing nuclear magnetic resonance to detect multi-cancer signatures across diverse tumor types from serum samples. Early clinical validation highlights promising sensitivity, particularly for notoriously lethal cancers like pancreatic carcinoma. Additionally, innovative urine-based tumor DNA tests are demonstrating efficacy in predicting bladder cancer recurrence following immunotherapy, potentially revolutionizing personalized oncology monitoring. These developments underscore a shift toward functional biomarker detection beyond traditional genetic assays.